White paper: Landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 5, 2013, Pages

  Vlasakakis, G ^a   Comets, E ^b   Keunecke, A ^c   Gueorguieva, I ^d   Magni, P ^e   Terranova, N ^e   Della Pasqua, O ^a   De Lange, E C ^f   Kloft, C ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b INSERM   (France)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d Global PK PD Department   (United Kingdom)

^e UNIVERSITY OF PAVIA   (Italy)

^f LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPETENCE FRAMEWORK; CONCEPTUAL FRAMEWORK; DATA BASE; DRUG DISEASE MODELING AND SIMULATION; HUMAN; MODEL; PHARMACOLOGY; PHARMACOMETRICS; PRIORITY JOURNAL; SIMULATION;

EID: 84881167489     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.16     Document Type: Article

References (30)

1. van der Graaf H. CPT: pharmacometrics and systems pharmacology. CPT Pharmacometrics Syst. Pharmacol. 1, e8 (2012).
2. Scannell, J.W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200 (2012).
3. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
4. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
5. Zhang, L., Pfister, M. & Meibohm, B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 10, 552-559 (2008).
6. Peck, C.C. Quantitative clinical pharmacology is transforming drug regulation. J. Pharmacokinet. Pharmacodyn. 37, 617-628 (2010).
7. Stevens, J. et al. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J. Pharmacokinet. Pharmacodyn. 39, 463-477 2012).
8. Stroh, M. et al. Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event. AAPS J. 11, 99-108 (2009).
9. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
10. Bhattaram, V.A. et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 7, E503-E512 (2005).
11. Lee, J.Y. et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 50, 627-635 (2011).
12. Ribba, B. et al. A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin. Cancer Res. 18, 5071-5080 (2012).
13. Gobburu JVS. Pharmacometrics 2020. J. Clin. Pharmacol. 50 (suppl. 9), 151S-157S (2010).
14. Holford, N. & Karlsson, M.O. Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin. Pharmacol. Ther. 82, 103-105 (2007).
15. Barrett, J.S., Fossler, M.J., Cadieu, K.D. & Gastonguay, M.R. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J. Clin. Pharmacol. 48, 632-649 (2008).
16. Innovative Medicines Initiative. Research Agenda. 〈http://www.imi. europa.eu/content/research-agenda〉. Accessed 22 October 2012.
17. Wetherington, J.D. et al. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J. Clin. Pharmacol. 50, 31S-46S (2010).
18. Renub Research. Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016. (MarketResearch.com, Rockville, MD, 2012).
19. FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. 〈http://www.fda.gov/downloads/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm113411.pdf〉. (2004). Accessed 22 October 2012.
20. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and modelbased drug development. CPT Pharmacometrics Syst. Pharmacol. 1, e6 (2012).
21. DDMoRe. DDMoRe-Project. 〈http://www.ddmore.eu/project〉. Accessed 22 October 2012.
22. Carraccio, C., Wolfsthal, S.D., Englander, R., Ferentz, K. & Martin, C. Shifting paradigms: from Flexner to competencies. Acad. Med. 77, 361-367 (2002).
23. Gamson Z. Understanding the difficulties of implementing a competence-based curriculum. In Competence Based Education and Training. (ed. Burk, J.W). (Falmer Press, East Sussex, UK, 1989). ISBN 1-85000-626-1.
24. Whiddett S, Hollyforde S. The Competencies Handbook. (Institute of Personnel and Development, London, 1999).
25. Frank, J.R. et al. Competency-based medical education: theory to practice. Med. Teach. 32, 638-645 (2010).
26. NICE. A single competency framework for all prescribers. 〈http://www.npc.co.uk/improving-safety/improving-quality/resources/ single-comp-framework.pdf〉. (2012). Accessed 22 October 2012.
27. Bloom BS. Taxonomy of Educational Objectives: The Classification of Educational Goals. (McKay, New York, 1956).
28. Linstone HA, Turoff M, Helmer O. The Delphi Method: Techniques and Applications. (Addison-Wesley, Reading, Mass, 1975).
29. Team RC. R: A Language and Environment for Statistical. (R Foundation for Statistical Computing, Vienna, Austria, 2012).
30. UCE Birmingham Staff and Student Development Department. Guide to Learning Outcome. 〈http://www.ssdd.bcu.ac.uk/outcomes/ UCE%20Guide%20to%20Learning%20Outcomes%202006.pdf〉. (2006). Accessed 22 October 2012.